Vertex CF Combo Succeeds In Phase III, But Secondary Endpoints May Be Crucial
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex’s two-drug combo for cystic fibrosis hits primary and several key secondary endpoints in a pair of pivotal trials, although data from the primary endpoint underwhelms some observers. Strong data from a pair of secondary endpoints, however, may provide real-world strategic value for the combo.
You may also be interested in...
Vertex Phase III For CF Combo Shows Power Of “Breakthrough” Designation
Pivotal trials for the combination of Kalydeco and VX-809 will measure safety and efficacy over 24 weeks, whereas Kalydeco monotherapy gained FDA approval on the basis of 56 weeks of data; Vertex and FDA developed the protocol together following a recent “breakthrough therapy” designation for the two-drug combo.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.